Navigation Links
One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
Date:6/18/2013

BURLINGTON, Mass., June 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the past 12 months, 25 percent of surveyed physicians from the EU5 (France, Germany, Italy, Spain and the United Kingdom) have been required to change the antiretroviral (ARV) prescription for some or most of their HIV patients, primarily to reduce costs. Additionally, more than 40 percent of respondents report that changing prescriptions is strongly encouraged or that they give preference to lower priced ARVs. These findings reflect the tightening healthcare budgets throughout the EU5 as over 20 percent of surveyed physicians indicate that their budgets for ARV treatments have decreased in the last year.  

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The new European Physician and Payer Forum report entitled The Approaching Cliff: How Will the Availability of Generic Antiretrovirals Impact the EU5 Prescribing and Reimbursement Landscape for Current and Emerging Brands in HIV? finds that surveyed physicians currently prescribe once-daily, single tablet regimens (STRs), such as Gilead/Bristol-Myers Squibb's Atripla and Gilead/Janssen's Eviplera to more than 40 percent of their HIV patients. Furthermore, despite cost containment efforts from payers and the upcoming generic availability of some STR components, the convenience of one pill dosed once daily, the recent launch of Gilead's integrase inhibitor-based STR Stribild, and the anticipated availability of ViiV's 572-Trii will drive respondents to expand use of STRs to half of their HIV patients by the end of 2014.

The report also finds that the serious public health threat posed by ongoing transmission of HIV and pushback from well-organized and influential patient advocates will constrain payers' ability to mandate use of cheaper multi-pill regimens. However, interviewed payers do believe that declining budgets and increasing numbers of patients requiring treatment will drive physicians to "break" coformulated, single pill products into multi-pill regimens to some extent in order to capture generic savings and meet their growing clinical burdens.

"Historically, new HIV agents have not been subjected to cost-effectiveness analyses owing to the serious public health threat posed by HIV infections and limited availability of effective drugs," said Decision Resources Analyst Seamus Levine-Wilkinson, Ph.D. "However, the pressure to reduce costs while providing treatment to more patients will drive increasingly stringent payer reviews in which competitive pricing and regionally tailored dossiers will play critical roles in securing formulary placement. Payers in the United Kingdom, in particular, warn that companies that resist price negotiations are being unrealistic and run the risk of losing out to more amenable drug developers."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
2. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
3. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
4. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
5. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
6. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
7. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
8. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
9. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
10. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
11. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016   Health 2.0 , the premiere ... technologies, announced today " 10 Year Global Retrospective ", ... over the past ten years.   ... Health 2.0 has served as the preeminent thought-leader in ... thousands of technologies, companies, innovators, and patient-activists through an ...
(Date:2/11/2016)... MARIETTA, Ga. , Feb. 11, 2016  MiMedx ... medicine company utilizing human amniotic membrane and other birth ... proprietary platforms to develop and market advanced products and ... RBC Capital Markets, 2016 Global Healthcare Conference in ... Petit, Chairman and CEO, Michael J. Senken , ...
(Date:2/11/2016)... PORTLAND, Ore. , Feb. 11, 2016 /PRNewswire/ ... pleased to announce the acquisition of SolutionsRx, a full-service ... access hospitals. Along with providing traditional contract pharmacy services, ... to assist clients in navigating the complex 340B regulatory ... of Wellpartner. --> James R. Love , ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Clinical Data Management Solution Providers list for its expertise in eClinical Solutions. DDi ... expertise to serve the technology needs of global clients. DDi provides smarter technology ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, ... demanding job, and no time to decompress, Rabinowitz found herself drawn to a casual ... for its impact on her life, implementing a 20-minute-per-day meditation practice with her team. ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
Breaking Medicine News(10 mins):